Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

ASH 2025

Published: 18 Dec 2025

Views: 8

Rating:

Save

Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France

Prof Jean-Jacques Kiladjian discusses the ongoing phase III ROP-ET study evaluating ropeginterferon alfa-2b in patients with essential thrombocythemia who are intolerant, resistant, or ineligible for standard cytoreductive therapies. He outlines the unmet need in this population, the study design and endpoints, and the favourable tolerability observed to date ahead of the planned 12-month primary efficacy analysis.

Related Videos

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights...

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Oncologists' perspectives and practices on minimal residual disease testing in...

Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA

Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma ( Dr Fathima Shehnaz Ayoobkhan - Internal Medicine Resident, Pontiac, USA )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

More from ecancer